Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer

作者：Xingxing Huang, Kun Ke, Weiwei Jin, Qianru Zhu, Qicong Zhu, Ruyi Mei, Ruonan Zhang, Shuxian Yu, Lan Shou, Xueni Sun, Jiao Feng, Ting Duan, Yiping Mou, Tian Xie, Qibiao Wu, Xinbing Sui · 发表于：Frontiers in Immunology · 年份：2022 · DOI：10.3389/fimmu.2022.887048 · 被引用次数：46 · 研究领域：Colorectal Cancer Treatments and Studies、Ferroptosis and cancer prognosis、Cancer Immunotherapy and Biomarkers

Background Colorectal cancer (CRC) is one of the most common malignancies and its incidence and mortality are increasing yearly. 5-Fluorouracil (5-FU) has long been used as a standard first-line treatment for CRC patients. Although 5-FU-based chemotherapy is effective for advanced CRC, the consequent resistance remains a key problem and causes the poor prognosis of CRC patients. Thus, there is an urgent need to identify new biomarkers to predict the response to 5-FU-based chemotherapy. Methods CRC samples were retrieved from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). The immune-related genes were retrieved from the ImmPort database. Single-cell sequencing results from colorectal cancer were obtained by the ArrayExpress database. 5-FU resistance-related genes were filtered and validated by R packages. ESTIMATE algorithms were used to assess the tumor microenvironment (TME). KEGG and GO analysis were performed to explore the biological signaling pathway for resistant-response patients and sensitive-response patients in the tumor microenvironment. pRRophetic algorithms were used to predict 5-FU sensitivity. GSEA and GSVA analysis was performed to excavate the biological signaling pathway of the RBP7 gene. Results Nine immune-related genes were identified to be associated with 5-FU resistance and poor disease-free survival (DFS) of CRC patients and the signature of these genes was developed in a DFS-prognostic model. Four immune-related genes were determine...